Focused On-demand Library for Conserved oligomeric Golgi complex subunit 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9H9E3

UPID:

COG4_HUMAN

Alternative names:

Component of oligomeric Golgi complex 4

Alternative UPACC:

Q9H9E3; B4DMN8; C9JS23; Q96D40; Q9BRF0; Q9BVZ2; Q9H5Y4; Q9Y3W3

Background:

Conserved oligomeric Golgi complex subunit 4, also known as Component of oligomeric Golgi complex 4, is pivotal for normal Golgi function. It facilitates SNARE-pin assembly and Golgi-to-ER retrograde transport through its interaction with SCFD1. This protein's role underscores the intricate mechanisms ensuring cellular cargo transport and processing.

Therapeutic significance:

The protein is linked to Congenital disorder of glycosylation 2J and Saul-Wilson syndrome, diseases stemming from gene variants affecting this protein. Understanding its function could pave the way for innovative treatments targeting these genetic disorders, highlighting its therapeutic potential.